Effects of basic carbohydrate counting versus standard outpatient nutritional education (The BCC Study): study protocol for a randomised, parallel open-label, intervention study focusing on HbA1c and glucose variability in patients with type 2 diabetes

被引:6
|
作者
Ewers, Bettina [1 ]
Bruun, Jens Meldgaard [2 ,3 ]
Vilsboll, Tina [1 ,4 ]
机构
[1] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[2] Steno Diabet Ctr Aarhus, Aarhus, Denmark
[3] Univ Aarhus, Dept Clin Med, Aarhus, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
来源
BMJ OPEN | 2019年 / 9卷 / 11期
关键词
MANAGEMENT; LITERACY; NUMERACY; ADULTS; PREVENTION; CONSENSUS; THERAPY; SKILLS;
D O I
10.1136/bmjopen-2019-032893
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Recommendations on energy intake are key in body weight management to improve glycaemic control in people with type 2 diabetes (T2D). International clinical guidelines recommend a variety of eating patterns to promote energy restriction as the primary dietetic approach to body weight control in managing T2D. In addition, individualised guidance on self-monitoring carbohydrate intake to optimise meal timing and food choices (eg, basic carbohydrate counting (BCC)) is recommended to achieve glycaemic control. However, the evidence for this approach in T2D is limited. The objective of this study was to compare the effect of an educational programme in BCC as add-on to the usual dietary care on glycaemic control in people with T2D. Methods and analyses The study is designed as a randomised, controlled trial with a parallel-group design. The study duration is 12 months with data collection at baseline, and after 6 and 12 months. We plan to include 226 adults with T2D. Participants will be randomised to one of two interventions: (1) BCC as add-on to usual dietary care or (2) usual dietary care. The primary outcome is changes in glycated haemoglobin A1c or mean amplitude of glycaemic excursions from baseline and after 6-month intervention between and within study groups. Further outcome measures include changes in time in range, body weight and composition, lipid profile, blood pressure, mathematical literacy skills, carbohydrate estimation accuracy, dietary intake, diet-related quality of life, perceived competencies in diet and diabetes and perceptions of an autonomy supportive dietician-led climate, physical activity and urinary biomarkers.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study
    Junyu Pei
    Xiaopu Wang
    Zeyu Pei
    Xinqun Hu
    Cardiovascular Diabetology, 22
  • [32] Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
    Kameda, Reina
    Nomoto, Hiroshi
    Cho, Kyu Yong
    Kawata, Shinichiro
    Omori, Kazuno
    Takeuchi, Jun
    Nagai, So
    Kurihara, Yoshio
    Aoki, Shin
    Nakamura, Akinobu
    Atsumi, Tatsuya
    Miyoshi, Hideaki
    BMJ OPEN, 2020, 10 (02):
  • [33] Correction to: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Matthias Blüher
    Julio Rosenstock
    Josef Hoefler
    Raymond Manuel
    Anita M. Hennige
    Diabetologia, 2024, 67 : 758 - 758
  • [34] Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study
    Pei, Junyu
    Wang, Xiaopu
    Pei, Zeyu
    Hu, Xinqun
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [35] Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blueher, Matthias
    Rosenstock, Julio
    Hoefler, Josef
    Manuel, Raymond
    Hennige, Anita M.
    DIABETOLOGIA, 2024, 67 (03) : 470 - 482
  • [36] Efficacy of lispro mix 25 BID versus glargine QD as starter insulin in patients with type 2 diabetes stratified by baseline HbA1c: subgroup analysis of a multi-national, randomized, open-label, parallel, controlled trial (DURABLE)
    Hou, Jianing
    Cao, Dachuang
    Qian, Lei
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 15 - 15
  • [37] Effects of long-term HbA1c variability on serious infection risks in patients with type 2 diabetes and the influence of age, sex and ethnicity: A cohort study of primary care data
    Carey, Iain M.
    Critchley, Julia A.
    Chaudhry, Umar A. R.
    Cook, Derek G.
    DeWilde, Stephen
    Limb, Elizabeth S.
    Bowen, Liza
    Woolford, Stephen
    Whincup, Peter H.
    Sattar, Naveed
    Panahloo, Arshia
    Harris, Tess
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 211
  • [38] Effectiveness of a Video-Based Lifestyle Education Program Compared to Usual Care in Improving HbA1c and Other Metabolic Parameters in Individuals with Type 2 Diabetes: An Open-Label Parallel Arm Randomized Control Trial (RCT)
    Uttio Gupta
    Yashdeep Gupta
    Divya Jose
    Kalaivani Mani
    Viveka P. Jyotsna
    Gautam Sharma
    Nikhil Tandon
    Diabetes Therapy, 2020, 11 : 667 - 679
  • [39] Effectiveness of a Video-Based Lifestyle Education Program Compared to Usual Care in Improving HbA1c and Other Metabolic Parameters in Individuals with Type 2 Diabetes: An Open-Label Parallel Arm Randomized Control Trial (RCT)
    Gupta, Uttio
    Gupta, Yashdeep
    Jose, Divya
    Mani, Kalaivani
    Jyotsna, Viveka P.
    Sharma, Gautam
    Tandon, Nikhil
    DIABETES THERAPY, 2020, 11 (03) : 667 - 679
  • [40] Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study
    Truman, Lucy A.
    Pekalski, Marcin L.
    Kareclas, Paula
    Evangelou, Marina
    Walker, Neil M.
    Howlett, James
    Mander, Adrian P.
    Kennet, Jane
    Wicker, Linda S.
    Bond, Simon
    Todd, John A.
    Waldron-Lynch, Frank
    BMJ OPEN, 2015, 5 (12):